Janet Midega is a Science program officer in Wellcome’s Drug-Resistant Infections (DRI) team where she is leading research activities within the antimicrobial resistance (AMR) scope of Wellcome’s priority program on DRI. She provides scientific leadership, program development, and management support to the AMR surveillance and epidemiology program with a focus on determining the global burden of antimicrobial resistance. She also manages a science and policy program in AMR which aims at evaluating how legislative changes banning antibiotic use in animal meat production can reduce the potential transfer of resistant pathogens between animals and humans; as well as a surveillance program on the development of a comprehensive data capture system for patient-focussed AMR surveillance in LMIC settings. In line with the DRI programmes interest in accelerating the development of new antibiotics, Janet works closely with CARB-x based at the Boston University, USA to support the discovery and development of novel antibiotics, as part of Wellcome’s role as an accelerator and support for companies joining CARBx.
Janet joined Wellcome in February 2018 after more than ten years of research in the biology of disease vectors and the genetic epidemiology of malaria. As a contributor to the Anopheles gambiae 1000genomes project, she conducted academic research at the University of Oxford, Big Data Institute; working in collaboration with the KEMRI- Wellcome Trust Research Programme, Kenya where she was a Senior Scientist. Prior to that, she was a postdoctoral scientist at Imperial College, London studying Anopheles mosquito immunity to malaria. Janet obtained a Masters degree in entomology and a Ph.D. in Zoology from the University of Ghana. She has extensive experience in field sampling, data capture, epidemiology, surveillance and control of infectious diseases. She is also a 2017 Aspen New Voices Fellow in Public Health; Aspen Institute, Washington DC.